Efficacy and Safety of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation in East Asia with Atrial Fibrillation S. Goto 1, J. Zhu 2, L. Lisheng 2, BH. Oh 3, D. Wojdyla 4, M. Hanna 5, J. Horowitz 6, L. Wallentin 7, D. Xavier 8, JH. Alexander 4 (1) Tokai University School of Medicine, Isehara, Japan (2) Fuwai Hospital, Beijing, China, People's Republic of (3) Seoul National University Hospital, Seoul, Korea, Republic of (4) Duke Clinical Research Institute, Duke University Medical Center, Durham, United States of America (5) Bristol-Myers Squibb, Princeton, United States of America (6) University of Adelaide, Australia (7) Uppsala University, UCR-Uppsala Clinical Research Center, Uppsala, Sweden (8) St. John's Research Institute, Bangolore, India
Global Collaboration 39 countries, 1034 sites, 18, 201 patients Norway: 90 Canada: 1057 United States: 3433 Mexico: 609 Colombia: 111 Peru: 213 Poland: 314 Sweden: 217 Denmark: 339 U. K. : 434 Netherlands: 309 Belgium: 194 Germany: 854 France: 35 Spain: 230 Czech Rep: 165 Austria: 34 Italy: 178 Brazil: 700 Israel: 344 1, 993 patients were recruited from East Asian countries including China (n=843), Japan (n=336), South Korea (n=310), Philippines(n=205), Malaysia (n=126), Hong Kong (n=76) and Singapore (n=40) Finland: 26 Hungary: 455 Romania: 274 Ukraine: 956 Russia: 1800 Turkey: 6 China: 843 India: 601 Malaysia: 126 Japan: 336 South Korea: 310 Taiwan: 57 Hong Kong: 76 Philippines: 205 Singapore: 40 Chile: 258 South Africa: 89 Argentina: 1561 Bristol-Myers Squibb and Pfizer Australia: 322
Primary Efficacy Endpoint
Primary Safety Endpoint
Primary Safety Endpoint
Conclusion- East Asia vs Non East Asia • The ARISTOTLE trial enrolled over 1900 patients from East Asian countries. These patients were of lower body weight and tended to have poorer INR control with warfarin. • Despite similar CHADS 2 scores, the overall rate of stroke was higher in East Asian than non-East Asian patients. • Apixaban had consistent benefits when compared with warfarin on stroke or systemic embolism in East Asian and non-East Asian patients. • A tendency toward a greater reduction in bleeding was seen with apixaban compared with warfarin in East Asian compared with non. East Asian patients. • Rates of intracranial bleeding on warfarin were higher in East Asian than non-East Asian patients. • These data support that apixaban is an attractive alternative to warfarin among East Asian as well as non-East Asian patients with nonvalvular AF.
Скачать презентацию Efficacy and Safety of Apixaban Compared with Warfarin
ad905f8fe799ec5065420d7d68fd61ae.ppt